Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection.
Pancreatectomy
Pancreatic intraductal neoplasms
Recurrence
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 May 2022
29 May 2022
Historique:
received:
29
11
2021
accepted:
26
04
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
The international consensus guidelines for intraductal papillary mucinous neoplasm of the pancreas (IPMN) presented clinical features as indications for surgery. Whereas surveillance for recurrence, including de novo lesions, is essential, optimal surveillance protocols have not been established. This study aimed to assess the clinical features of recurrence at the remnant pancreas (Rem-Panc) and extra-pancreas (Ex-Panc) after surgery for IPMN. Ninety-one patients of IPMN that underwent detailed preoperative assessment and pancreatectomy were retrospectively analyzed, focusing especially on the type of recurrence. The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). Recurrence was observed in 26 patients (29%), of which recurrence was seen at Rem-Panc in 19 patients (21%) and Ex-Panc in 7 patients (8%). The frequency of Rem-Panc recurrence was 10% in LDA, 21% in HDA, and 37% in IPMC. On the other hand, Ex-Panc recurrence was observed only in IPMC (23%). Ex-Panc recurrence showed shorter median recurrence-free survival (RFS) and overall survival (OS) than Rem-Panc recurrence (median RFS 8 months vs. 35 months, p < 0.001; median OS 25 months vs. 72 months, p < 0.001). Regarding treatment for Rem-Panc recurrence, repeat pancreatectomy resulted in better OS than no repeat pancreatectomy (MST 36 months vs. 15.5 months, p = 0.033). On multivariate analysis, main duct stenosis or disruption as a preoperative feature (hazard ratio [HR] 10.6, p = 0.002) and positive surgical margin (HR 4.4, p = 0.018) were identified as risk factors for Rem-Panc recurrence. The risk factors for Rem-Panc and Ex-Panc recurrence differ. Therefore, optimal surveillance on these features is desirable to ensure that repeat pancreatectomy for Rem-Panc recurrence can be an appropriate surgical intervention.
Sections du résumé
BACKGROUND
BACKGROUND
The international consensus guidelines for intraductal papillary mucinous neoplasm of the pancreas (IPMN) presented clinical features as indications for surgery. Whereas surveillance for recurrence, including de novo lesions, is essential, optimal surveillance protocols have not been established.
AIM AND METHODS
OBJECTIVE
This study aimed to assess the clinical features of recurrence at the remnant pancreas (Rem-Panc) and extra-pancreas (Ex-Panc) after surgery for IPMN. Ninety-one patients of IPMN that underwent detailed preoperative assessment and pancreatectomy were retrospectively analyzed, focusing especially on the type of recurrence.
RESULTS
RESULTS
The IPMNs were finally diagnosed as low-grade dysplasia (LDA, n = 42), high-grade dysplasia (HAD, n = 19), and invasive carcinoma (IPMC, n = 30). Recurrence was observed in 26 patients (29%), of which recurrence was seen at Rem-Panc in 19 patients (21%) and Ex-Panc in 7 patients (8%). The frequency of Rem-Panc recurrence was 10% in LDA, 21% in HDA, and 37% in IPMC. On the other hand, Ex-Panc recurrence was observed only in IPMC (23%). Ex-Panc recurrence showed shorter median recurrence-free survival (RFS) and overall survival (OS) than Rem-Panc recurrence (median RFS 8 months vs. 35 months, p < 0.001; median OS 25 months vs. 72 months, p < 0.001). Regarding treatment for Rem-Panc recurrence, repeat pancreatectomy resulted in better OS than no repeat pancreatectomy (MST 36 months vs. 15.5 months, p = 0.033). On multivariate analysis, main duct stenosis or disruption as a preoperative feature (hazard ratio [HR] 10.6, p = 0.002) and positive surgical margin (HR 4.4, p = 0.018) were identified as risk factors for Rem-Panc recurrence.
CONCLUSIONS
CONCLUSIONS
The risk factors for Rem-Panc and Ex-Panc recurrence differ. Therefore, optimal surveillance on these features is desirable to ensure that repeat pancreatectomy for Rem-Panc recurrence can be an appropriate surgical intervention.
Identifiants
pubmed: 35643422
doi: 10.1186/s12885-022-09650-w
pii: 10.1186/s12885-022-09650-w
pmc: PMC9148522
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
588Informations de copyright
© 2022. The Author(s).
Références
Ann Surg. 2015 May;261(5):976-83
pubmed: 24979607
Ann Surg. 2015 Dec;262(6):1108-14
pubmed: 25793719
J Gastroenterol. 2020 Jan;55(1):86-99
pubmed: 31463655
J Gastrointest Surg. 2013 Sep;17(9):1618-26
pubmed: 23813047
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Pancreas. 2010 Jul;39(5):658-61
pubmed: 20173669
Medicine (Baltimore). 2019 Nov;98(47):e18039
pubmed: 31764824
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Ann Diagn Pathol. 2015 Oct;19(5):347-52
pubmed: 26265194
Pancreatology. 2006;6(1-2):17-32
pubmed: 16327281
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
J Clin Gastroenterol. 2011 Oct;45(9):755-8
pubmed: 21602701
Ann Surg. 2016 Jun;263(6):1180-7
pubmed: 26334637
Arch Surg. 2008 Jul;143(7):639-46; discussion 646
pubmed: 18645105
J Am Coll Surg. 2007 May;204(5):987-93; discussion 993-5
pubmed: 17481526
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
J Hepatobiliary Pancreat Sci. 2015 Oct;22(10):757-65
pubmed: 26148131
Gastroenterology. 2002 Nov;123(5):1500-7
pubmed: 12404225
Ann Surg. 2014 Feb;259(2):360-8
pubmed: 23989056
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):516-22
pubmed: 20714841
Dig Endosc. 2018 Sep;30(5):659-666
pubmed: 29675938
Ann Surg. 1997 Jun;225(6):637-44; discussion 644-6
pubmed: 9230804
HPB (Oxford). 2013 Oct;15(10):814-21
pubmed: 23782351
Surgery. 2010 Aug;148(2):285-90
pubmed: 20434746
Dig Surg. 2012;29(3):213-25
pubmed: 22677789
Pancreatology. 2012 May-Jun;12(3):183-97
pubmed: 22687371
Pancreas. 2015 Mar;44(2):311-20
pubmed: 25479586